Core Insights - Hikvision has significantly improved cash flow and accelerated net profit growth [1] - The company's accounts receivable and notes decreased by 4% year-on-year to 37.3 billion yuan by the end of Q2 [1] - Q2 revenue remained stable at approximately 23.3 billion yuan year-on-year, indicating high-quality business development [1] Business Developments - The company has launched hundreds of large model products covering cloud, edge, and domain applications [1] - Key products include structured cameras, smart perimeter cameras, document search servers, security inspection, and industrial flaw detection, which are widely used in manufacturing, electricity, urban governance, and traffic management [1] International Operations - Despite trade restrictions from the U.S. and Canada, the healthy development of overseas business demonstrates the company's strong resilience [1] - The comparable company's 26-year PE valuation level of 25 times suggests a target price of 43.00 yuan, maintaining a "buy" rating [1]

东方证券研报指出，具身智能场景应用浪潮加速，永创智能机器人有望加速推进。人形机器人场景应用 正在加速，饮料/包装/分拣领域需求大，有望成为重要应用。此前市场更多关注工厂内搬运场景，而该 行认为饮料包装和分拣领域也有望成为人形机器人的重要落地场景，因为饮料食品快递包装的分拣工作 对人工数量需求大、劳动强度高，但任务简单且重复性高，可能更快催化机器人应用落地。永创是饮料 包装自动化设备的龙头供应商，更懂行业需求。市场认为初创人形机器人企业可能最早推出适配产品， 但该行认为具有行业积淀的设备企业具备优势，有望更快推进机器人落地。2025年来，公司重视人形机 器人研发，已经注册部分人形机器人专利，并分别成立多家子公司进行布局，我们认为永创有望较快推 进人形机器人产品落地。参考可比公司估值，给予2025年的34倍PE，对应目标价为13.26元，维持"买 入"评级。 ...

Group 1 - The company, Boshi Co., Ltd. (SZ 002698), announced that it will participate in a research meeting organized by Dongfang Securities Asset Management Co., Ltd. on August 1, 2025 [2] - The company's director and board secretary, Chen Bo, will be involved in the meeting and will respond to questions from investors [2]

Group 1 - The company, Ningbo Jintian Copper Industry (Group) Co., Ltd., issued 14.5 million convertible bonds with a total amount of 1.45 billion yuan, which will be traded on the Shanghai Stock Exchange starting from August 28, 2023 [1][2] - The initial conversion price of the bonds was set at 6.75 yuan per share, which was later adjusted to 6.63 yuan per share due to the company's annual equity distribution [2][3] - The conversion price was further adjusted to 5.90 yuan per share following a board resolution and will remain at this level until the next adjustment [3][4] Group 2 - The company has a conditional redemption clause for the convertible bonds, which allows redemption if the stock price exceeds 130% of the conversion price for a specified period [5] - The redemption condition was met as the stock price was above 7.53 yuan per share for fifteen trading days [5][6] - The company decided to exercise its right to redeem the convertible bonds early, with the redemption price being the face value plus accrued interest [6][7] Group 3 - The company’s major shareholders and executives did not trade the convertible bonds within six months prior to the redemption condition being met [6] - The sponsor institution, Dongfang Securities, confirmed that the redemption process complied with relevant regulations and internal procedures [7]

格隆汇8月1日｜东方证券研报指出，洽洽食品预计上半年归母净利润为8,000–9,750万元，同比下降约 71–76%，主因是原料采购价格大幅上涨带动毛利率下行。公司25Q1收入同比下降13.7%，反映出主力 品类动销放缓、渠道去库存延续。该行判断，公司当前主动压缩利润释放节奏，在保证终端投放与品牌 维护的前提下进行结构优化，为后续增长修复创造空间。考虑到原料端成本上行叠加主力品类出货节奏 偏慢，公司上半年利润显著下滑，我们修正了瓜子与坚果等核心品类的销售增速、新品导入的放量节奏 及毛利率改善幅度等关键假设。据此调整公司盈利预测，预计公司2025–2027年EPS分别为 1.25/1.42/1.67元（前次预测2025/2026年EPS为2.42/2.75元）。考虑公司在渠道端持续推进精耕、海外市 场具备中长期潜力，参考当前可比公司估值水平，给予公司2025年21倍PE，对应目标价26.25元，维 持"买入"评级。 ...

Core Viewpoint - The report from Dongfang Securities indicates a sustained high growth in overseas data center-related CAPEX since the first half of 2024, with upward revisions to future expectations driven by AI demand [1] Group 1: CAPEX Trends - Overseas CSPs have revised their CAPEX expectations upward, indicating an improving investment climate for data centers [1] - Microsoft, Google, and Meta have all increased their CAPEX forecasts for Q2 2025, with Meta raising its full-year CAPEX expectation to $66-72 billion (previously $64-72 billion) and Google adjusting its FY2025 CAPEX to $85 billion (previously $75 billion) [1] - Microsoft’s Q2 2025 CAPEX is projected at $24.2 billion, with expectations to exceed $30 billion in Q3 2025, reflecting a year-on-year growth of over 50% [1] Group 2: Importance of Power Supply - The transition from traditional computing to intelligent computing has led to significant increases in power consumption, necessitating advancements in AIDC power supply technology [2] - The importance of high efficiency, high density, and high stability power supplies is expected to continue rising as AI demand evolves [2] - The entire power supply chain, from grid power (10kV+) to final chip (<1V), is undergoing technological upgrades, enhancing the value of power systems in AIDC [2] Group 3: Export Opportunities - The overseas AIDC CSP cycle is leading, with AI power supply exports likely to be the first beneficiaries of the AI technology infrastructure wave [3] - High barriers to entry in the overseas AIDC power market favor companies like Delta and Vertiv, which possess strong technical and ecological advantages [3] - As domestic Chinese companies continue to close the technology gap with Taiwanese and foreign firms, they are expected to benefit from the overseas AICAPEX boom [3] Group 4: Investment Recommendations - Companies in the AIDC power sector that are likely to benefit from the improving overseas investment climate include Magpower (002851.SZ), Hewei Electric (603063.SH), Xinle Energy (300593.SZ), Tonghe Technology (300491.SZ), Oulu Tong (300870.SZ), and Zhongheng Electric (002364.SZ) [4] - In the AIDC power supply segment, key companies to watch include Jinpan Technology (688676.SH), Mingyang Electric (301291.SZ), Weiteng Electric (688226.SH), and Liangxin Co., Ltd. (002706.SZ) [4]

Group 1 - The core viewpoint of the article highlights that Aide Biology's semi-annual report shows strong performance, demonstrating growth resilience despite challenges in the IVD industry [1] - The IVD industry is currently facing pressure on growth due to medical insurance cost control and extended hospital payment cycles [1] - Starting from 2025, the value-added tax rate on the company's reagent sales will increase from 3% to 13% [1] Group 2 - Aide Biology is a leader in tumor drug companion diagnostics, with a comprehensive range of products and multiple exclusive approvals, contributing to stable revenue performance [1] - The main revenue source is testing reagents, which generated revenue of 480 million yuan, a year-on-year increase of 7.9%, accounting for 83.4% of total revenue, with a gross margin of 90.7% [1] - Technical services and testing services generated revenues of 60 million yuan (down 5.0% year-on-year) and 30 million yuan (up 0.9% year-on-year), respectively [1] Group 3 - The company's overseas business showed stable performance, achieving revenue of 110 million yuan in the first half of 2025, a year-on-year increase of 3.7%, accounting for 18.3% of total revenue [1] - Based on the average valuation of comparable companies for 2025, the company is given a target price of 26.56 yuan, corresponding to a price-to-earnings ratio of 32 times [1] - The rating for the company is maintained at "Buy" [1]

Core Viewpoint - The demand for localized AI deployment is rising, and the company is expected to benefit significantly from this trend [1] Group 1: AI Solutions and Performance - The company has upgraded its "Yiduo Cloud" solution to create an AI platform that better matches large model scenarios, focusing on intelligent computing and application development [1] - The AICP high-performance computing platform shows a performance improvement of 5-10 times compared to traditional Ollama architecture in multi-instance and high-concurrency scenarios, making it compatible with the latest large models, including DeepSeek [1] - The company's AI application innovation platform enables users to quickly build large model applications, simplifying the development and operation of AI applications [1] Group 2: Market Position and Valuation - The company's full-stack capabilities provide a "high-performance, high-security, high-value" one-stop solution for localized large model deployment, positioning it well to benefit from ongoing domestic substitution and growing AI demand [1] - Based on the comparable companies' 25-year PS level, the company is assigned a 25-year PS of 6.10 times, corresponding to a target price of 119.00 yuan, maintaining a "buy" rating [1]

东方证券研报指出，近期，朗新集团正式向全球首发自主研发的"朗新九功AI能源大模型"（简称"朗新 九功"），该模型数据智能体在BIRD-Bench国际评测基准中斩获双榜冠军。朗新九功模型深度融合 了"时序预测"与"AI智能体"双引擎技术，基于对中国能源市场全场景的数据沉淀与实践验证，打造出能 够解决能源行业复杂核心问题的垂直大模型。在全球权威的自然语言转SQL评测基准BIRD-Bench中， 九功模型凭借意图理解、推理分析与SQL生成能力获得了执行准确率（EX）与查询效率奖励（R- VES）双料冠军。认为九功模型能够斩获双榜冠军，彰显了朗新集团较强的AI技术实力，也为相关模型 在能源行业的落地打下良好基础。九功模型功能强大，赋能公司电力现货交易等新兴业务。随着香 港"稳定币+RWA"生态的发展，朗新有望凭借其较好的业务场景和先发优势，在绿色能源+区块链领域 成为重要的参与者和生态建设方，从而为自身业务发展和商业模式扩展提供助力。参照可比公司，认为 公司合理估值水平为2025年41倍市盈率，对应目标价为22.96元，维持"买入"评级。 ...

Core Viewpoint - Dongfang Securities report highlights that Ganli Pharmaceutical's innovative drug data is impressive, particularly the glucose-lowering effects of GZR18, indicating strong future growth potential for the company [1] Group 1: Drug Development and Clinical Data - Ganli Pharmaceutical has leading R&D expenditures in the industry, with multiple key products gradually disclosing Phase II clinical data since 2025 [1] - GZR18 (Bofang Glutide) shows superior glucose-lowering effects in Type 2 diabetes patients, with HbA1c and weight reductions exceeding those of the Semaglutide group after 24 weeks of biweekly injections [1] - After 23 weeks of treatment, GZR18 subjects experienced an average weight loss of 6.92 kg, representing a 9.3% reduction from baseline [1] - The Phase II clinical data for GZR4, an insulin weekly formulation, indicates good safety and a more significant reduction in HbA1c compared to daily insulin degludec (Novo Nordisk) in patients with poor baseline insulin control after 16 weeks of treatment [1] Group 2: Market Outlook and Valuation - The company anticipates a substantial 32.6% increase in the volume of its third-generation insulin agreements in the upcoming centralized procurement in 2024, alongside a rebound in product prices [1] - Leveraging the market coverage advantages gained from centralized procurement, the company's annual performance expectations are further solidified [1] - The company is assigned a 37x PE valuation for 2025, corresponding to a target price of 70.67 yuan, maintaining a "buy" rating [1]